RE: Synairgen’s IP25 Apr 2020 18:28
Second this. Financial statements show this risk:
Competition risk
The Group’s current and potential competitors include
pharmaceutical and biotechnology companies and academic
institutions, many of whom have significantly greater financial
resources than the Group. There can be no assurance that
competitors will not succeed in developing products that are
more effective or economic than any developed by the Group,
or which would render the Group’s products non-competitive
or obsolete.